BET Inhibition Enhances Chemotherapy-Induced Antitumor Immunity by Limiting Macrophage Recruitment in Triple-Negative Breast Cancer
Authors:
- Songyin HuangSHSongyin Huang
- Yue ChenYCYue Chen
- Jiawei WangJWJiawei Wang
- Jueqiong XuJXJueqiong Xu
- Yaofeng ZhouYZYaofeng Zhou
- Tengyao WangTWTengyao Wang
- Jiajun HuangJHJiajun Huang
- Fuxiang WangFWFuxiang Wang
- Huosheng ZhouHZHuosheng Zhou
- Qiang LiuQLQiang Liu
- Yan BaoYBYan Bao
Preprint
- 12 November 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Chemotherapy can promote antitumor immunity in part by inducing immunogenic forms of tumor cell death, providing a rationale for combining cytotoxic agents with immunomodulatory therapies. However, chemotherapy-treated tumors may also develop myeloid-dominated microenvironments that restrict effective T cell responses. Here, we investigated whether bromodomain and extraterminal domain inhibition (BETi) could improve the immune response elicited by liposomal doxorubicin (Doxil) in triple-negative breast cancer (TNBC). Methods We evaluated JQ1 combined with Doxil in orthotopic 4T1 and EMT6 TNBC models, with other BET inhibitors and cisplatin used to examine broader applicability. Transcriptomic profiling, flow cytometry, immunofluorescence, and molecular assays characterized immune responses. T cell depletion, nude mice, and tumor rechallenge assessed immune dependence and memory. Macrophage recruitment was investigated using tumor profiling and in vitro migration assays. Results JQ1 enhanced Doxil-mediated tumor control in both models, prolonged survival in 4T1 mice, and induced complete, recurrence-free regression in EMT6 mice following repeated treatment. Additional BET inhibitors also enhanced chemotherapy efficacy. Antitumor benefit was lost in nude mice and attenuated by CD8 + T cell depletion. Combination treatment increased intratumoral T cell infiltration and activation, effector memory responses, granzyme B expression, and tumor apoptosis, while conferring resistance to rechallenge. JQ1 can reduce chemotherapy-associated macrophage accumulation, decreased CD206 and increased CD86 expression, and inhibited macrophage migration toward CCL2 and chemotherapy-treated tumor cells. Conclusions These findings suggest that BETi can improve chemotherapy-induced antitumor immunity by limiting macrophage recruitment and thereby creating a tumor microenvironment more permissive for CD8 + T cell-mediated tumor control.All Related Versions
This publication has 47 references indexed in Scilit:
- Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastasesCancer Cell, 2026
- A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial—Pembrolizumab Low dose in Addition to NACT in TNBC)Annals of Oncology, 2025
- Clinical translation of nanomedicines for brain diseases: Current challenges and future directionsJournal of Controlled Release, 2025
- Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacyCancer Cell, 2024
- Cisplatin-based combination therapies: Their efficacy with a focus on ginsenosides co-administrationPharmacological Research, 2024
- Nanodrugs mediate TAMs-related arginine metabolism interference to boost photodynamic immunotherapyJournal of Controlled Release, 2024
- Delineating the tumour microenvironment response to a lipid nanoparticle formulationJournal of Controlled Release, 2022
- Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancerCancer Cell, 2021
- Macrophages and Therapeutic Resistance in CancerCancer Cell, 2015
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011